chronic myeloid leukaemia
Novartis’s Tasigna scores EU approval in paediatric patients
November 20, 2017Sales and Marketing Europe, Novartis, Tasigna, chronic myeloid leukaemia, pharma
Novartis’s Tasigna (nilotinib) has received European Commission approval for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in …
NICE thumbs up for BMS leukaemia treatment
November 18, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, NICE, Sprycel, chronic myeloid leukaemia
Bristol-Myers Squibb has announced that NICE have given a Final Appraisal Determination recommending Sprycel (dasatinib) for the treatment of chronic …
Precision medicine reveals ‘Achilles heel’ in chronic myeloid leukaemia
September 16, 2016Medical Communications University of Glasgow, chronic myeloid leukaemia
Scientists at the University of Glasgow believe they have revealed an ‘Achilles heel’ of chronic myeloid leukaemia (CML), making their …
Helsinn and MEI Pharma join forces to develop leukaemia drug Pracinostat
August 9, 2016Manufacturing and Production, Research and Development Helsinn, MEI Pharma, Pracinostat, chronic myeloid leukaemia
Swiss pharmaceutical group Helsinn has entered an agreement with MEI Pharma over the licensing, development and commercialisation of Pracinostat (SB939) …
NHS restriction of CML treatment in England criticised
August 27, 2015Medical Communications, Sales and Marketing NHS, NICE, chronic myeloid leukaemia, leukaemia
Medical experts have criticised NHS cost regulators’ decision to limit the use of Ariad’s Iclusig (ponatinib) in the treatment of …
Trial hitch for Pfizer’s leukaemia drug submission plans
December 7, 2010Research and Development, Sales and Marketing CML, Gleevec, Glivec, Pfizer, bosutinib, chronic myeloid leukaemia
Pfizer is pressing ahead with plans to submit bosutinib for European approval despite the chronic myeloid leukaemia drug missing its …
